GlassScriptPhysician profile
James Watkins
NPI 1811047905
$1,154.83
in general payments reported to CMS, 2019-2025
27 companies · $339 in 2025
The $339 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $60.16 · 2020: $16.57 · 2021: $38.63 · 2022: $169 · 2023: $221 · 2024: $310 · 2025: $339.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $853 · Education: $17.02.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $853.25 |
| Education | $17.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $303.72 | 2022-2025 | Reblozyl, Pomalyst, Pomalyst |
| Pfizer INC. | $103.08 | 2019-2025 | |
| Springworks Therapeutics, INC. | $86.04 | 2024-2025 | Ogsiveo |
| Novartis Pharmaceuticals Corporation | $76.67 | 2022-2025 | |
| Gilead Sciences, INC. | $59.60 | 2021-2025 | Trodelvy |
| Galvanize Therapeutics, INC | $58.41 | 2025 | Aliya System |
| Abbvie INC. | $54.40 | 2024-2025 | |
| Seagen INC. | $39.10 | 2022-2023 | Padcev |
| Janssen Biotech, INC. | $30.57 | 2022-2024 | Rybrevant |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $28.06 | 2019-2023 | Xifaxan, Trulance |
| Amgen INC. | $27.75 | 2022 | |
| Array Biopharma INC | $27.30 | 2025 | Lorbrena, Padcev, Braftovi |
| Medtronic, INC. | $26.71 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $26.60 | 2019-2023 | Iclusig |
| Incyte Corporation | $20.17 | 2023 | Monjuvi |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Octapharma USA, INC. | $17.26 | 2023 | Panzyga |
| Regeneron Healthcare Solutions, INC. | $17.02 | 2024 | Libtayo |
| Eisai INC. | $16.79 | 2025 | |
| Glaxosmithkline, LLC. | $16.64 | 2025 | Ojjaara |
| E.R. Squibb & Sons, L.L.C. | $16.57 | 2020 | |
| Epizyme, INC. | $16.47 | 2022 | |
| Merck Sharp & Dohme LLC | $15.38 | 2019 | |
| Daiichi Sankyo INC. | $14.94 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $14.51 | 2023 | Lynparza |
| Adaptive Biotechnologies Corporation | $14.47 | 2022 | |
| Genmab U.S., INC. | $14.44 | 2024 | Epkinly |
| Emd Serono, INC. | $12.16 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Watkins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.